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Progressive, Irreversible Loss of Vision: Gyrate Atrophy of the 
Choroid and Retina 
 
Sina Vahedi* 
Department of Biology 
Lake Forest College 
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Summary 
 
In our highly visual society, a genetic disease that 
gradually dims one’s vision must be seen as a cruel 
and debilitating disease. One such disease is the 
gyrate atrophy of the choroid and retina (GA), an 
autosomal recessive disease caused by mutations 
in the gene encoding the mitochondrial enzyme 
ornithine aminotransferase (OAT). GA is 
characterized by early onset myopia and night-
blindness followed by cataracts and progressive 
loss of peripheral vision culminating in complete 
blindness. More than 60 mutations in the gene 
coding for OAT cause the 150 known cases of GA 
by an unknown mechanism. Clinical genetic tests 
are available and should be carried out if there is a 
family history of the disease, as early dietary 
restriction of arginine and clinical doses of vitamin 
B6 slow its progression. Experiments in cultured 
epidermal keratinocytes show promise towards 
gene therapy for GA. Future research should be 
geared towards understanding the molecular basis 
of GA and finding a permanent cure. 
 
Introduction 
 
Gyrate atrophy of the choroid and retina (GA) is a rare, 
mostly Finnish, autosomal recessive inborn error of 
metabolism disease caused by a mutation in the 
nuclear gene which codes for the mitochondrial protein 
ornithine aminotransferase (OAT) (Valle and Kaiser-
Kupfer, 1982). The symptoms of GA include myopia 
early in the first decade of the patient’s life followed by 
night-blindness, cataracts, reduced peripheral vision, 
and progressive narrowing of the visual field (tunnel 
vision) due to the death of cells in the choroid and 
retinal regions of the eye in sharply demarcated circular 
regions. The disease culminates in total loss of vision 
by the age of 30 or 40, as the regions of gyrate atrophy 
progressively increase and consolidate (Valle and 
Kaiser-Kupfer, 1982).  
Biochemically, GA is characterized by 
elevated plasma ornithine concentrations 
(hyperornithinemia), and lowered proline and creatine 
concentrations not accompanied by hyperammonemia 
(Valle & Simell, 2001). This distinction serves to 
distinguish GA from other urea cycle diseases like 
hyperammonemias, as well as from hyperornithinemia-
hyperammonemia-homocitrullinuria syndrome, which is 
the other hyperornithinemia. 
 
Impact of GA 
 
Our eyes enable us to distinguish friend from foe, 
recognize foods and avoid things that cause us harm; 
they provide an extraordinary evolutionary advantage in 
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by Dr. Karen Kirk.  
our world. This is apparent from the fact that different 
types of eyes have evolved independently multiple 
times in the animal kingdom. 
We are a very visual society. Our attention to 
television, art and architecture attest to that, as do 
phrases like ‘seeing is believing.’ The development of a 
written language and the prominence of the internet 
have cemented the importance of vision in our life. The 
biological and cultural significance of sight makes an 
inherited disease like GA an important one to study. 
I am personally attracted to the study of this disease 
because it initially affects night vision. I find that the 
night makes most things appear more sublime and 
serene. It is my favorite time, and I would hate to lose 
my ability to appreciate the beauty of the night. Our 
society is also becoming more night oriented since we 
are no longer dependant on sunlight, which further 
increases the burden on GA patients.  
Also, I think of my world in a very visual 
way—I learn things by writing and reading them, I love 
photography, the movies and architecture—and 
therefore I consider our sense of sight to be more 
important than our senses of touch, taste, and hearing. 
 
The Aberrant Macromolecule: OAT 
 
Ornithine aminotransferase (OAT) is a nuclear encoded 
mitochondrial matrix enzyme that is the primary 
catabolic enzyme for the non-protein amino acid 
ornithine (Inana et al, 1989). It catabolizes ornithine to 
pyrroline-5-carboxylate (PC) with the help of the 
coenzyme pyridoxal phosphate and thence to 
glutamate or proline (see figure 1).  
Ornithine is an important component of the 
urea cycle, which is responsible for reducing the 
nitrogen burden in the body by removing the toxic 
ammonia—formed as a result of amino acid 
catabolism—from the body by converting it to urea. 
Ornithine is the primary acceptor of ammonia in the 
urea cycle and, since the urea cycle occurs partly in the 
cytoplasm and partly in the mitochondrial matrix, 
ornithine along with citrulline are essential for the 
complete turn of the urea cycle.  
OAT is translated in the cytoplasm as a 48 
kDa precursor containing a leader sequence that allows 
its transport to the mitochondrion (Inana et al, 1989). 
This leader sequence is cleaved in the mitochondrial 
matrix to give rise to the 45 kDa mature protein. Four to 
six of the proteins come together to form the active 
quaternary structure of the enzyme (Inana et al, 1989). 
There are more than 60 known mutations in 
the gene coding for OAT that lead to GA (Wang et al. 
2000). Each mutation has a different effect on the gene 
product and thus might give rise to a slightly different 
form of GA. There are many known nonsense codon 
mutations that lead to reduced OAT mRNA (Mahima et 
al., 1992), and microdeletions that lead to splicing 
defects (McClatchey et al., 1990), as well as many point 
mutations including those that lead to the loss of the 
initiator codon (Mitchell et al., 1988).  
It is remarkable that such a large number of 
mutations are known to cause this rare disease with 
only about 150 biochemically-documented cases (Valle 
& Simell, 2001). This suggests that OAT could be a 
very sensitive protein, and that changing its primary
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Figure 1. The Urea Cycle, showing the role of ornithine and OAT. CAP is carbamyl phosphate, the source of fixed ammonia in the 
mitochondria. The figure is modified from Valle and Kaiser-Kupfer (1982). 
 
structure even slightly affects its ability to form the 
functional homo-tetramer. This allelic heterogeneity 
could also imply that the nature of the gene is such that 
it is more susceptible to mutations.  
A small subset of these cases are of a form 
of GA called pyridoxine (vitamin B6) responsive GA 
since the progress of the disease can be stemmed by 
pharmacological doses of vitamin B6 (Valle, & Simell, 
2001). This type of GA is caused by mutations in 
regions of the gene coding for OAT that are responsible 
for its binding to its coenzyme pyridoxal phosphate. 
This form of the disease is rarer, and known to be 
caused by 3 mutations; V332M, A226V, and E318K 
(Valle & Simell, 2001, and Michaud et al, 1995). 
 
Molecular Basis of GA 
 
The molecular basis of GA and its primary targeting of 
cells of the choroid and retina are the disease’s 
greatest mysteries (Valle, & Simell, 2001). The 
complexity in determining the molecular model of the 
disease lies in the fact that this model must explain the 
hyperornithinemia without an accompanying 
hyperammonemia. It must also explain the limited 
involvement of other organ systems, and elucidate the 
reason for the progressive degeneration seen in this 
disease.  
Three possible models are described by 
Weleber, et al. (2003). The first supposes a direct toxic 
effect of ornithine on the pigmented epithelium. 
According to this model, high levels of ornithine have a 
direct toxic influence by some unknown mechanism. 
Supporters of this model cite as evidence for this model 
the fact that reduction of ornithine levels is sufficient to 
treat GA (Wang, et al., 2000). This evidence cannot rule 
out the second hypothesized model. 
The second model states that the 
suppression of proline synthesis (due to the inhibitory 
effect of accumulated ornithine) is the molecular cause 
of the disease. Proline can be synthesized in the body 
from PC, which is the product of ornithine catabolism by 
OAT. This is the major or only pathway for proline 
synthesis in many tissues in the body (Valle & Simell, 
2001). Therefore it is possible that high levels of 
ornithine have an indirect toxic effect in the body due to 
the lowering of proline levels. This model is supported 
by an experiment conducted by Ueda et al, in 1998 in 
human retinal pigmented epithelial cells where they 
used an irreversible inhibitor of OAT to cause ornithine 
cytotoxicity. This toxicity was prevented by supplying 
the cells with proline. 
The third disease model identifies the 
suppression of the synthesis of creatine and creatine 
phosphate in the retina as the culprit in GA. High levels 
of ornithine inhibit the working of glyceraldehyde 
transamidinase, which is the first enzyme in creatine 
synthesis  (Valle and Kaiser-Kupfer, 1982). Treatment 
of GA by supplying high levels of creatine helps 
alleviate some muscle abnormalities seen in GA 
patients but does not stop the ocular progression of the 
disease suggesting that creatine does not play a major 
role in the chorio-retinal atrophy  (Valle and Kaiser-
Kupfer, 1982). 
An additional level of complexity arises due to 
the rarity and heterogeneity of the disease, the fact that 
it is not known which type of cell in the retina is affected 
first, and also due to the fact that cells in the retina are 
highly interdependent (Valle & Simell, 2001) and may 
die due to pressures from neighboring cells.  
 
The OAT Gene 
 
Mitchell et al. and O’Donnell et al. (1988) found that the 
OAT gene was located on the human chromosome 10. 
Mitchell et al. (1988) showed that the gene is 21 
kilobase pairs in length, and contains 11 exons with 
exon 2 being almost always absent from all mRNA 
transcripts. Interestingly, the translated region for the 
gene begins in exon 3 as opposed to the first two exons.  
Low stringency southern blots of human DNA 
probed with OAT cDNA indicate the presence of 
multiple OAT pseudogenes on the short arm of the X 
chromosome (Valle & Simell, 2001). Pseudogenes are 
sequences in the genome that are evolutionarily related 
to a gene, no longer code for a protein, but may play a 
role in regulating the gene expression (Gibbs, W. W., 
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2003). The OAT pseudogenes, however, appear to be 
non-functional (Valle & Simell, 2001). 
OAT is expressed in hepatocytes, renal 
tubular cells, brain, neural retina, retinal pigment 
epithelium, and greatly expressed in neonatal intestinal 
cells (Wang, et al., 1995). This widespread expression 
requires an explanation for the fact that GA affects 
primarily the retina. 
 
Model Organisms 
 
Wang et al (1995) created the first knockout mice 
homozygously lacking OAT. Interestingly, the lack of 
OAT was fatal to these mice, and they exhibited an 
unexpected hypoornithinaemia. This shed light on the 
different role of OAT in neonatal and adult mice. In 
neonatal mice, OAT is required to synthesize ornithine 
from glutamate. This ornithine is then used to 
synthesize arginine, which is needed by the quickly 
growing mouse but is not available in required amounts 
in its diet. At an older age, when the need for arginine is 
fulfilled, the role of OAT is reversed: it becomes 
involved in breaking down ornithine and giving rise to 
glutamate or proline. Thus, thus mice lacking OAT 
develop hyperornithinemia and the symptoms of GA. 
The hypoornithinaemia in neonatal mice encouraged 
researchers to look at human infants who had GA (this 
was not previously possible since GA symptoms don’t 
manifest themselves until well within the first decade of 
patients’ lives). They found that human infants also 
exhibited hypoornithinaemia. Thus, mice were 
established as a good model organism for the study of 
GA and gave great insight into the role of OAT from the 
beginning. 
In 1996, Wang et al. used the mouse model 
to follow up on the initial observations from the previous 
study and provided good evidence that, in mice, the 
retinal pigment epithelial (RPE) cells are the initial site 
of attack because they were the first to show signs of 
pathological changes in two month old mice. 
The mouse model was also used to provide 
evidence in support of the idea that ornithine itself has a 
direct toxic effect in GA (Wang et al., 2000). Mice 
deficient in OAT and expressing hyperornithinemia 
were maintained on an arginine restricted diet at the 
age of three weeks, which led to a reduction of ornithine 
in their system to normal levels. This reduction of 
ornithine accumulation correlated with a prevention of 
retinal degeneration suggesting that the reduction of 
ornithine accumulation is sufficient to treat GA (Wang et 
al., 2000). 
 
Genetic Tests and Treatment 
 
Clinical genetic tests for OAT deficiency are available in 
a lab in Finland (EDDNAL, 2002) and six labs in the 
United States (NHLBI, 2004). If there is a family history 
of GA, the test should be carried out because finding 
the disorder early allows the disease to be treated and 
the condition stabilized.  
The three main GA treatments are ornithine 
reduction by restriction of arginine in the diet and 
augmentation of renal loss, creatine supplementation 
since creatine levels are lower in GA patients, and 
administration of pharmacological doses of pyridoxine 
(for pyridoxine-responsive GA). Of these treatments, 
dietary arginine restriction has been shown to be most 
successful (Valle, & Simell, 2001). These diets are 
often supplemented by synthetic sources of amino 
acids, which are quite expensive; however, Santinelli et 
al. (2004) showed in a 26 year follow-up study that a 
natural low-protein diet is sufficient to reduce ornithine 
accumulation in the body and thus can be used to 
retard GA progress. 
Sullivan et al. (1997) devised a novel 
approach to reduce ornithine accumulation in the body. 
Their approach involves setting up a metabolic sink to 
reduce ornithine levels. In a proof of concept paper, 
they over-expressed OAT in keratinocytes cultured from 
a GA patient by transducing the cell using an 
adenovirus vector. They showed that these cells 
remove ornithine from the media they are bathed in 
much faster than normal keratinocytes. In addition, 
Christensen et al. prepared a 2002 clinical trial at the 
NIH in which a small patch of keratinocytes were 
grafted onto the thigh of a GA patient to check the 
efficacy of this treatment. Results of this study remain 
to be evaluated. If successful, this treatment would 
provide an easier and more permanent alternative to 
current treatment methods requiring precise and 
ongoing dietary restrictions. 
None of the current treatments repair 
damage caused by the disease; rather, they attempt to 
stabilize the patient’s condition. Eye transplants could 
serve as a short-term solution for the disease, but the 
high levels of ornithine in the body will eventually cause 
transplanted organs to deteriorate. If applied early 
enough, the metabolite sink method could prove to be a 
suitable treatment for GA. However, more permanent 
cures need to be found that will halt the disease early in 
the life of the patient. Gene therapy, despite its present 
shortcomings, may one day prove quite valuable for GA 
treatment. 
 
Looking to the Future 
 
Research in the field of GA has done a lot to explain the 
role of OAT in the body and has demonstrated methods 
to prevent the progress of the disease. However, many 
questions still remain unanswered. The molecular 
model of the disease must be elucidated, and further 
studies should be conducted to determine why it 
primarily targets the chroroid and the retina. 
Understanding the mechanism of the disease is 
essential to finding a permanent cure for it. 
Also, there is much evidence and argument 
that GA might not just be a disease of the eye, butis 
rather a systemic disease involving the central and 
peripheral nervous system (Peltola, et al. 2002). This 
may explain why none of the treatments are effective 
one hundred percent of the time, and it is an important 
concept to investigate in the future. 
 
Note: Eukaryon is published by students at Lake Forest 
College, who are solely responsible for its content. The 
views expressed in Eukaryon do not necessarily reflect 
those of the College. Articles published within Eukaryon 
should not be cited in bibliographies. Material contained 
herein should be treated as personal communication 
and should be cited as such only with the consent of 
the author. 
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